Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

AIDS DRUG BLOCK GRANTS FUNDED AT $30 MIL. for fiscal 1990 under the House/Senate compromise HHS appropriations bill. House and Senate wrapped up a conference on the measure Oct. 5. The full House endorsed the compromise Oct. 11 by a 364-56 vote; Senate floor action is yet to be scheduled. The grants will be administered by the HHS Health Resources and Services Administration. "The conferees have provided $30 mil. for the AIDS drug reimbursement program," the report notes. "The conferees direct the [HHS] secretary to permit the states to make available to eligible individuals therapeutics determined to prolong life or prevent the serious deterioration of health arising from AIDS or HIV infection." The earlier Senate version of the bill had provided $30 mil., while the House bill contained no funding for the AIDS grants. Sen. Kennedy (D-Mass.) has been a strong supporter of the program. The grants have primarily been used in the past for subsidizing the cost of Burroughs Wellcome's Retrovir (AZT). However, HRSA specifically notified state programs in the past that funds would also be available for Lyphomed's aerosolized pentamidine, Nebupent, and alpha interferon marketed by Schering-Plough and Hoffmann-La Roche ("The Pink Sheet" Feb. 27, T&G-3). Supplemental appropriations may be necessary to keep the program operating, the report points out, due at least in part to the price of Burroughs Wellcome's Retrovir (AZT). Maintaining that the price of AZT is still too high, even with the recent, second 20% price cut, the conferees urge Burroughs Wellcome to consider further action to make the drug more accessible to low-income patients. The report states: "The conferees remain concerned about the price of AZT. Even with the recent price reduction by the manufacturer of the drug, AZT remains prohibitively expensive for most AIDS patients. While the conferees are providing additional funds for the AIDS drug reimbursement program, the conferees strongly urge the manufacturer of AZT to take further steps to make the drug more widely accessible to low-income patients." The federal program began in 1988 to give states funds to provide drugs to low-income AIDS patients. Initially it was envisioned as a one-time effort to give states time to set up their own funding mechanisms, but the program was extended twice during 1989 ("The Pink Sheet" April 10, T&G-4). Total 1989 funding was $20 mil. -- including $15 mil. reprogrammed from other HHS activities and $5 mil. provided by Burroughs Wellcome. Burroughs Wellcome announced its 20% reduction in the price of AZT on Sept. 18. That same day, Rep. Waxman (D-Calif.) met with company officials, seeking answers to a series of questions related to the costs and the price of the drug ("The Pink Sheet" Sept. 25, T&G-5). Waxman is considering hearings on the issue.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts